Skip to content

An observational study of antivascular endothelial growth factor inhibitors in punctate inner choroidopathy

An observational study of antivascular endothelial growth factor inhibitors in punctate inner choroidopathy

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2200067141
Enrollment
Unknown
Registered
2022-12-27
Start date
2021-08-09
Completion date
Unknown
Last updated
2023-05-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

punctate inner choroidopathy

Interventions

Observation group 2:No

Sponsors

ZhongShan Ophthalmic Center SUN YAT-SEN UNIVERSITY
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: observation group one inclusion criteria(1)age =18 years old; (2) Patients with active PIC diagnosed by detailed ophthalmologic examination and fluoroscopy, with secondary CNV and in active phase;(3) Treated only with intravitreal anti-VEGF agents;(4) Be able to finish the follow-up examination Inclusion criteria for the observation group two: (1) age = 18 years; (2) PIC affected eyes with stage II-III PIC lesions outside the central macular sulcus present by detailed ophthalmologic examination and fluoroscopy, and no secondary CNV in the study eye; (3) Not receiving any treatment; (4) Those who could complete follow-up as required.

Exclusion criteria

Exclusion criteria: Subjects were excluded if there was evidence of an alternative diagnosisfor example, multifocal choroiditis andpanuveitis, acute posterior multifocal placoid pigment epithelium,multiple evanescent ,serpiginouschoroidalatrophy and other subtype Subjects were excluded if there was evidence of an alternative diagnosisfor example, multifocal choroiditis andpanuveitis, acute posterior multifocal placoid pigment epithelium,multiple evanescent white dot syndrome ,serpiginouschoroidalatrophy;if the subject had a history of intravitreal anti-VEGF injection or systemic immunosuppressants during past 3months ; if the subject was complicated with ocular infection or inflammation, as to the diagnosis.

Design outcomes

Primary

MeasureTime frame
;

Secondary

MeasureTime frame
area of PIC lesions;

Countries

China

Contacts

Public ContactFeng Wen

ZhongShan Ophthalmic Center SUN YAT-SEN UNIVERSITY

wenfeng208@foxmail.com13725112111

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026